Once-Monthly Subcutaneously Administered Risperidone in the Treatment of Schizophrenia: Patient Considerations

Lesia V Tchobaniouk1 Department of Pharmacy, North Memorial Health Hospital, Robbinsdale, MN, USA

https://orcid.org/0000-0003-0019-8478

Erin E McAllister2 Department of Pharmacy, Clement J. Zablocki VA Medical Center, Milwaukee, WI, USA

https://orcid.org/0000-0002-2452-3282

Danielle L Bishop3 Department of Pharmacy, M Health Fairview St. Joseph’s Hospital, St. Paul, MN, USA

Rachel M Carpentier4 Department of Pharmacy, Fairview Pharmacy Services, Minneapolis, MN, USA

Katharine R Heins4 Department of Pharmacy, Fairview Pharmacy Services, Minneapolis, MN, USA

https://orcid.org/0000-0002-9712-3597

Robert J Haight5 Pharmacy Services, University of Minnesota Medical Center, Minneapolis, MN, USA

Jeffrey R Bishop6 Department of Experimental and Clinical Pharmacology, College of Pharmacy, University of Minnesota, Minneapolis, MN, USA;7 Department of Psychiatry, Medical School, University of Minnesota, Minneapolis, MN, USACorrespondence[email protected]

show all

Citations (2)

Keep up to date with the latest research on this topic with citation updates for this article.

Once-Monthly Subcutaneously Administered Risperidone in the Treatment of Schizophrenia: Patient Considerations

Articles from other publishers (2)

Information for

Open access

Opportunities

Help and information

Your download is now in progress and you may close this window

Login or register to access this feature

Once-Monthly Subcutaneously Administered Risperidone in the Treatment of Schizophrenia: Patient Considerations

Citations (2)

Articles from other publishers (2)

Related research

To cite this article:

Download citation

Information for

Open access

Opportunities

Help and information

Keep up to date